Latest Conference Articles

December 10th 2017, 4:03am

ASH Annual Meeting and Exposition

The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.

December 10th 2017, 2:03am

ASH Annual Meeting and Exposition

Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.

December 9th 2017, 9:32pm

ASH Annual Meeting and Exposition

Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.

December 9th 2017, 3:35am

San Antonio Breast Cancer Symposium

Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.

December 9th 2017, 2:44am

San Antonio Breast Cancer Symposium

Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

December 9th 2017, 1:59am

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

December 9th 2017, 1:38am

San Antonio Breast Cancer Symposium

Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer

December 9th 2017, 12:58am

San Antonio Breast Cancer Symposium

Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.

December 9th 2017, 12:57am

San Antonio Breast Cancer Symposium

Harold Burstein, MD, PhD, medical oncologist, Dana-Farber Cancer Institute discusses some key findings from the follow-up data from the SOFT trial.

December 9th 2017, 12:19am

San Antonio Breast Cancer Symposium

Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.

December 8th 2017, 11:42pm

San Antonio Breast Cancer Symposium

Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.

December 8th 2017, 11:00pm

San Antonio Breast Cancer Symposium

Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts

December 8th 2017, 7:36pm

San Antonio Breast Cancer Symposium

The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.

December 8th 2017, 6:57pm

San Antonio Breast Cancer Symposium

Dawn Hershman, MD, MS, professor of Medicine and Epidemiology, Columbia University Medical Center, discusses the use of acupuncture to treat joint pain caused by aromatase inhibitors in patients with breast cancer.

December 8th 2017, 4:55am

San Antonio Breast Cancer Symposium

Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.

December 8th 2017, 4:23am

San Antonio Breast Cancer Symposium

Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses some questions that remain after the recent phase II MEDIOLA trial.

December 8th 2017, 3:35am

San Antonio Breast Cancer Symposium

Halle Moore, MD, medical oncologist, the Cleveland Clinic, discusses the use of GnRH agonists to preserve ovarian function and fertility in women with breast cancer.

December 8th 2017, 2:12am

San Antonio Breast Cancer Symposium

Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.

December 8th 2017, 1:58am

ASH Annual Meeting and Exposition

Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.

December 7th 2017, 11:16pm

San Antonio Breast Cancer Symposium

Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.